American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 840-849, November 2009

Nephrotic Syndrome in Diabetic Kidney Disease: An Evaluation and Update of the Definition

  • Nicholas Stoycheff, MD, MS

      Affiliations

    • Division of Nephrology, Tufts Medical Center, Boston, MA
    • Corresponding Author InformationAddress correspondence to Nicholas Stoycheff, MD, MS, Division of Nephrology, Tufts Medical Center, 800 Washington St, Box 391, Boston, MA 02111
  • ,
  • Lesley A. Stevens, MD, MS

      Affiliations

    • Division of Nephrology, Tufts Medical Center, Boston, MA
  • ,
  • Christopher H. Schmid, PhD

      Affiliations

    • Division of Clinical Care Research, Biostatistics Research Center, Tufts Medical Center, Boston, MA
  • ,
  • Hocine Tighiouart, MS

      Affiliations

    • Division of Clinical Care Research, Biostatistics Research Center, Tufts Medical Center, Boston, MA
  • ,
  • Julia Lewis, MD

      Affiliations

    • Division of Nephrology, Vanderbilt Medical Center, Nashville, TN
  • ,
  • Robert C. Atkins, MD

      Affiliations

    • Department of Nephrology, Monash Medical Centre, Victoria, Australia
  • ,
  • Andrew S. Levey, MD

      Affiliations

    • Division of Nephrology, Tufts Medical Center, Boston, MA

Received 19 December 2008; accepted 15 April 2009. published online 26 June 2009.

Background

Nephrotic syndrome is defined as urine total protein excretion greater than 3.5 g/d or total protein–creatinine ratio greater than 3.5 g/g, low serum albumin level, high serum cholesterol level, and peripheral edema. These threshold levels have not been rigorously evaluated in patients with diabetic kidney disease or by using urine albumin excretion, the preferred measure of proteinuria in patients with diabetes.

Study Design

Diagnostic test study.

Setting & Participants

Adults with type 2 diabetes, hypertension, and urine total protein level greater than 0.9 g/d enrolled in the Irbesartan in Diabetic Nephropathy Trial.

Index Test

Baseline measures of proteinuria (total protein and albumin excretion and protein-creatinine and albumin-creatinine ratios). Linear regression to relate measures.

Reference Test

Other signs and symptoms of nephrotic syndrome at baseline (serum albumin < 3.5 g/dL, serum total cholesterol > 260 mg/dL or use of a statin, and edema or use of a loop diuretic); progression of chronic kidney disease during follow-up (doubling of baseline serum creatinine level or requirement for dialysis or kidney transplantation). Logistic regression to relate index and reference tests.

Results

In 1,608 participants, total urine protein level of 3.5 g/d was equivalent to urine albumin level of 2.2 g/d (95% confidence interval, 1.4 to 3.5). Of 1,467 participants, 641 (44%) had urine total protein level of 3.5 g/d or greater at baseline, 132 (9%) had other signs and symptoms of nephrotic syndrome at baseline, and 385 (26%) had progression of kidney disease during a mean follow-up of 2.6 years. Areas under the receiver operating curves for measures of proteinuria were 0.80 to 0.83 for other signs and symptoms of nephrotic syndrome and 0.72 to 0.74 for kidney disease progression. Threshold levels for nephrotic-range proteinuria and albuminuria were close to the points of maximal accuracy for both outcomes.

Limitations

Study population limits generalizability; inability to adjust for several variables known to affect serum albumin levels; lack of spot urine samples.

Conclusions

The historical definition of nephrotic-range proteinuria appears reasonable in patients with diabetic kidney disease. Equivalent thresholds for nephrotic-range albuminuria and albumin-creatinine ratio are 2.2 g/d and 2.2 g/g, respectively.

Index Words: Nephrotic syndrome, urine protein, urine albumin, proteinuria, albuminuria, protein-creatinine ratio, albumin-creatinine ratio, diabetic kidney disease, edema, hypercholesterolemia, hypoalbuminemia, chronic kidney disease progression, CKD

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi: 10.1053/j.ajkd.2009.04.016 on June 26, 2009.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Robert Nelson, MD, PhD, National Institutes of Health) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(09)00651-9

doi:10.1053/j.ajkd.2009.04.016

American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 840-849, November 2009